Apobiologix focuses its activities on the commercialization of biosimilars. Apobiologix’s biosimilar program is a natural extension of Apotex’s long-standing history of promoting access to affordable, high-quality medicines in Canada and around the world. We aim to transform access to affordable treatment through innovation, development and partnerships, in oncology and other areas.
At Apobiologix, we believe that invention is not the only form of innovation; we believe that health care professionals and patients deserve access to affordable treatments, without compromising on efficacy, quality and safety. Apobiologix is a pioneer and leader in the field of biosimilars in oncology in Canada. We offer you a filgrastim with short action as well as long action; Grastofil and Lapelga. Apobiologix offers a patient support program, the Answers program. It is an effective and fast program that helps access the drug for all patients.
Established in 2010, EMREACH helps expedite patient access to medications by utilizing the digital capabilities of EMRs (Electronic Medical Records). As the largest provider of drug-related digital forms (e.g., PSP Enrollment Forms) to Health Care Providers (HCPs) in ambulatory EMRs, EMREACH is leveraging and seeking to improve technological efficiencies for the benefit of HCPs in all health care settings. For more information, please contact Dave.Bard@emreach.ca.
We’re a company that takes on the toughest health challenges.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca and www.abbvie.com. Follow @abbviecanada on Twitter or find us on Facebook, LinkedIn and Instagram.
Our mission is to build the first next-generation biopharmaceutical company — one that expands the highest quality therapies to billions more people — through courage, persistent innovation, and challenging the status quo
Astellas Pharma Canada, Inc. is committed to providing patients, customers, community and employees with a bright future by changing tomorrow.
Astellas stands on the forefront of healthcare change, turning innovative science into value for patients This commitment is made possible because we are a different kind of pharmaceutical company. Headquartered in Markham, Ontario, Astellas Pharma Canada, Inc. is recognized as the first Japanese pharmaceutical company in Canada.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a focus on the discovery, development and commercialization of primary and specialty care medicines that transform lives. Our primary focus is on four important areas of healthcare: Cardiovascular, Renal and Metabolic disease; Oncology; Respiratory & Immunology; and Rare Diseases. AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients worldwide. In Canada, we employ roughly 1,100 employees across the country and our headquarters are located in Mississauga, Ontario. The company invested $112 million in Canadian research and development in 2020 and is designated a Global Clinical Trial Delivery site – leading the delivery of more than 100 global clinical trials in oncology and respiratory disease. For more information, please visit the company’s website at www.astrazeneca.ca.
AQCAMO seeks to improve the lives of cancer patients. To do so, we are dedicated to making oncology drugs more accessible to patients. With the help of our coordinators, we support and assist patients and their families by alleviating the financial burden caused by their cancer diagnosis to the best of our abilities.
We help patients and their families research, complete and submit their applications to the appropriate financial aid and support programs. In addition, we are committed to sharing knowledge and providing training and networking opportunities to all of our access coordinators.